Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma <i>in situ</i> of the bladder
Michael S. Cookson(University of Oklahoma Health Sciences Center), Ronald Tutrone(The University of Texas System), Samira Q. Harper(Endo Pharmaceuticals (United States)), Sam S. Chang(Vanderbilt University), Zhihui Lang(Bayer (China)), Christine Lihou(Structural Analytics (United States)), Thomas Li(Endo Pharmaceuticals (United States))
Cited by 50
Related Papers
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
|The Journal of Urology|1997|555